Study guide
18.2 Diagnostic Test Metrics & Screening
NBME Comprehensive Basic Science Examination CBSE
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Navigation
1.1 Current Exam Facts & Administration 1.2 Content Blueprint & Physician Tasks 1.3 Scoring, Score Reports & Step 1 Readiness
2 Human Development
2.1 Embryology & Congenital Development Patterns 2.2 Normal Age-Related Findings & Well-Patient Care
3 Blood & Hematologic Disease
3.1 Hematopoiesis, RBC Disorders & Anemias 3.2 Hemostasis, Thrombosis & Coagulopathies 3.3 WBC Disorders, Leukemia & Lymphoma Mechanisms
4 Immune System
4.1 Innate & Adaptive Immunity Mechanisms 4.2 Hypersensitivity, Autoimmunity & Immunodeficiency 4.3 Transplant Immunology & Immune Pharmacology
5 Nervous System Anatomy & Disease
5.1 Neuroanatomy Localization & Pathways 5.2 Stroke, Infection, Demyelination & Trauma 5.3 Seizures, Movement Disorders & Neurodegeneration 5.4 Special Senses: Eye & Ear Mechanisms
6 Behavioral Health
6.1 Psychiatric Disorders & Diagnostic Patterns 6.2 Psychopharmacology Mechanisms 6.3 Neurotransmitters, Learning & Behavioral Science
7 Musculoskeletal System
7.1 Bone Physiology, Fracture Healing & Bone Pathology 7.2 Joint Disease, Rheumatology & Connective Tissue 7.3 Muscle, NMJ & Peripheral Nerve Disorders
8 Skin & Soft Tissue
8.1 Dermatopathology High-Yield Lesions 8.2 Inflammation, Wound Healing & Soft-Tissue Infection
9 Cardiovascular Pathophysiology
9.1 Cardiac Cycle, Hemodynamics & Murmurs 9.2 Ischemic Heart Disease & Cardiomyopathy 9.3 Congenital & Valvular Heart Disease 9.4 Vascular Pathology & Hypertension
10 Cardiovascular Pharmacology
10.1 Antihypertensives, Heart Failure & Antiarrhythmics 10.2 Antiplatelets, Anticoagulants & Lipid Drugs
11 Respiratory System
11.1 Pulmonary Mechanics & Gas Exchange 11.2 Obstructive, Restrictive & Vascular Lung Disease 11.3 Pulmonary Infections, Neoplasms & Respiratory Pharmacology
12 Renal Physiology & Electrolytes
12.1 Nephron Transport & Renal Physiology 12.2 Electrolyte Disorders 12.3 Acid-Base Physiology & Compensation
13 Renal Pathology
13.1 Glomerular Disease Mechanisms 13.2 Tubulointerstitial, Vascular & Stone Disease
14 Gastrointestinal System
14.1 GI Physiology, Motility & Digestion 14.2 Esophagus, Stomach & Intestinal Pathology 14.3 Liver, Biliary Tree & Pancreas 14.4 GI Microbiology, Nutrition & Malabsorption
15 Endocrine System
15.1 Hormone Signaling & Hypothalamic-Pituitary Axes 15.2 Thyroid & Parathyroid Disease 15.3 Adrenal Disorders & Steroid Pharmacology 15.4 Diabetes, Glucose Homeostasis & Metabolic Syndrome
16 Reproductive System
16.1 Male & Female Reproductive Physiology 16.2 Pregnancy, Placenta & Developmental Toxicology 16.3 Reproductive Pathology & Hormone-Related Neoplasia
17 Multisystem Processes & Disorders
17.1 Cell Injury, Inflammation & Repair 17.2 Neoplasia Principles & Tumor Biology 17.3 Infection, Sepsis & Multisystem Microbial Disease 17.4 Genetics, Inborn Errors & Environmental Toxicology
18 Biostatistics & Epidemiology
18.1 Study Design, Bias & Causation 18.2 Diagnostic Test Metrics & Screening 18.3 Epidemiology Measures & Population Health
19 Social Sciences & Communication
19.1 Ethics Principles & Decision-Making Capacity 19.2 Communication Skills & Difficult Conversations 19.3 Professionalism, Systems & Practice-Based Learning
20 Integrated Disciplines Capstone
20.1 High-Yield Microbiology Anchors Across Systems 20.2 High-Yield Biochemistry & Molecular Mechanisms 20.3 Integrated Pharmacology Strategy & Exam-Day Execution
18.2 Diagnostic Test Metrics & Screening
Key Takeaways Explain This Topic AI
Sensitivity = TP/(TP+FN) (rule-out / SnNOut when high); specificity = TN/(TN+FP) (rule-in / SpPIn when high); neither depends on prevalence in the 2×2 used to compute them if disease status is known.
PPV = TP/(TP+FP) and NPV = TN/(TN+FN) move with prevalence: at low prevalence, even specific tests yield many false positives and low PPV; high prevalence raises PPV and lowers NPV.
Likelihood ratios: LR+ = sens/(1−spec); LR− = (1−sens)/spec; they reweight pre-test to post-test odds (Bayes) without being prevalence themselves.
ROC curves plot sensitivity vs 1−specificity across cutoffs; AUC summarizes discrimination; lowering the cut-point ↑sensitivity ↓specificity (and vice versa).
Parallel testing increases net sensitivity (fewer missed cases); serial/confirmatory testing increases net specificity (fewer false positives); screening criteria require important disease, acceptable test, effective earlier treatment, and acceptable false-positive burden.
Last updated: August 2026
18.2 Diagnostic Test Metrics & Screening
Quick Answer: Sn = TP/(TP+FN); Sp = TN/(TN+FP); PPV = TP/(TP+FP); NPV = TN/(TN+FN). Prevalence changes PPV/NPV, not intrinsic Sn/Sp. LR+ = Sn/(1−Sp); LR− = (1−Sn)/Sp. Parallel tests ↑net Sn; serial tests ↑net Sp. Screening needs important disease, good test, effective early treatment, and tolerable false-positive load.
Diagnostic reasoning on the CBSE is arithmetic plus epidemiology. Fill the 2×2 carefully, label each cell, compute the four core metrics, then ask how prevalence and cutoffs move the answers.
The 2×2 Table
Gold standard disease status defines columns; test result defines rows:
- Disease + Disease − Total
- Test + TP FP TP+FP
- Test − FN TN FN+TN
- Total TP+FN FP+TN N
- True positive (TP): disease present, test positive
- False positive (FP): disease absent, test positive
- False negative (FN): disease present, test negative
- True negative (TN): disease absent, test negative
Always verify column totals (people with/without disease) before computing.
Sensitivity, Specificity, PPV, NPV
Metric Formula Question answered Mnemonic
Sensitivity TP / (TP + FN) Of those with disease, who test positive? SnNOut: high Sensitivity, Negative → rules Out
Specificity TN / (TN + FP) Of those without disease, who test negative? SpPIn: high Specificity, Positive → rules In
- PPV TP / (TP + FP) Of positive tests, who truly have disease? Depends on prevalence
- NPV TN / (TN + FN) Of negative tests, who truly are disease-free? Depends on prevalence
Sensitivity and specificity are properties of the test in a defined population/method ; predictive values are properties of the test applied at a given prevalence (and spectrum of disease).
Worked example 1 — Full metrics from counts
A new D-dimer–like assay is studied in 1,000 patients with suspected disease; gold standard confirms disease in 200:
- Disease + Disease − Total
- Test + 180 160 340
- Test − 20 640 660
- Total 200 800 1,000
- Sensitivity = 180/200 = 0.90 (90%)
- Specificity = 640/800 = 0.80 (80%)
- Prevalence in sample = 200/1000 = 20%
- PPV = 180/340 ≈ 0.529 (53%)
- NPV = 640/660 ≈ 0.970 (97%)
Interpretation: a negative test is reassuring (high NPV here), but a positive test is only a coin-flip–ish for true disease at this prevalence—need confirmatory testing.
Worked example 2 — Same Sn/Sp, lower prevalence (PPV collapse)
Screen 10,000 asymptomatic people; true prevalence 1% (100 diseased, 9,900 healthy). Keep Sn 90%, Sp 80%:
- TP = 0.90 × 100 = 90
- FN = 10
- TN = 0.80 × 9,900 = 7,920
- FP = 9,900 − 7,920 = 1,980
- PPV = 90 / (90 + 1980) = 90/2070 ≈ 0.043 (4.3%)
- NPV = 7920 / (7920 + 10) ≈ 0.999
Teaching point: At low prevalence, most positive results are false positives. This is why screening tests need high specificity or a two-step strategy, and why PPV from referral clinics cannot be copied to community screening.
Worked example 3 — High prevalence setting
Same Sn 90%, Sp 80%, prevalence 50% in 1,000 people (500 diseased):
- TP = 450, FN = 50, TN = 400, FP = 100
- PPV = 450/550 ≈ 82%
- NPV = 400/450 ≈ 89%
PPV rose and NPV fell relative to the low-prevalence example— prevalence effect .
Likelihood Ratios and Bayes Intuition
Likelihood ratios (LRs) quantify how much a result shifts disease odds:
- LR+ = sensitivity / (1 − specificity) = true-positive rate / false-positive rate
- LR− = (1 − sensitivity) / specificity = false-negative rate / true-negative rate
Bayes update (odds form):
- Post-test odds = pre-test odds × LR
- Pre-test odds = p / (1 − p); post-test probability = odds / (1 + odds)
Rough clinical rules of thumb:
- LR Approximate shift
- LR+ > 10 Large increase in disease probability
- LR+ 5–10 Moderate increase
- LR+ 2–5 Small increase
- LR ≈ 1 No information
- LR− 0.2–0.5 Small decrease
- LR− 0.1–0.2 Moderate decrease
- LR− < 0.1 Large decrease
- Worked example 4 — LR and probability update
- From Example 1: Sn 0.90, Sp 0.80
- LR+ = 0.90 / 0.20 = 4.5
- LR− = 0.10 / 0.80 = 0.125
- Pre-test probability 20% → pre-test odds = 0.20/0.80 = 0.25
- Positive test → post odds = 0.25 × 4.5 = 1.125 → post probability = 1.125/2.125 ≈ 53% (matches PPV)
- Negative test → post odds = 0.25 × 0.125 = 0.03125 → post probability ≈ 3% (matches 1 − NPV)
LRs separate test discriminatory power from prevalence , then Bayes combines them—high-yield conceptual frame even when the stem only asks for LR+.
ROC Curves and Cut-Point Tradeoffs
Many tests are continuous (troponin, glucose, PSA). Choosing a cutoff defines positive vs negative:
- Lower cutoff → more positives → ↑sensitivity, ↓specificity (fewer FN, more FP)
- Higher cutoff → fewer positives → ↓sensitivity, ↑specificity (more FN, fewer FP)
ROC curve: y-axis sensitivity; x-axis 1 − specificity (false-positive rate) as cutoff sweeps. AUC (area under ROC) summarizes discrimination: 0.5 = chance; 1.0 = perfect. Comparing AUCs compares tests independent of a single cutoff, but clinical use still needs a chosen threshold based on harms of FN vs FP.
Worked example 5 — Cutoff choice
Glucose cutoff for "abnormal":
- Cutoff Sensitivity Specificity
- 100 mg/dL 95% 70%
- 126 mg/dL 78% 92%
Screening when missing disease is costly may favor the lower cutoff (higher Sn); confirmatory diagnostic contexts may favor higher Sp. There is no universal "best" number without utilities.
Parallel vs Serial Testing
- Strategy Definition Net effect
- Parallel Multiple tests at once; positive if any positive ↑ net sensitivity, ↓ net specificity
Serial (sequential) Second test only if first positive; positive if all positive ↑ net specificity, ↓ net sensitivity
Worked example 6 — Independent tests (approximation)
Two tests each Sn 80%, Sp 90%, used in parallel for a patient who is positive if either is positive:
- Net sensitivity ≈ 1 − (1−0.8)(1−0.8) = 1 − 0.04 = 96%
- Net specificity ≈ 0.9 × 0.9 = 81% (both must be negative to call negative)
Serial: call disease only if both positive:
- Net sensitivity ≈ 0.8 × 0.8 = 64%
- Net specificity ≈ 1 − (1−0.9)(1−0.9) = 99%
- Exams use this for "screen with sensitive test, confirm with specific test."
- Screening Criteria (Wilson–Jungner Style Teaching)
Population screening of asymptomatic people is justified only when a package of conditions holds (classic public-health teaching, not a single law):
- Important health problem (severity and/or frequency)
- Accepted treatment for recognized disease
- Facilities for diagnosis and treatment available
- Latent or early symptomatic stage exists
- Suitable test or examination (accurate, acceptable, safe)
- Test acceptable to the population
- Natural history adequately understood
- Agreed policy on whom to treat
- Cost balanced against expenditure on medical care as a whole
- Case finding should be a continuous process , not a one-off
CBSE framing: if early treatment does not improve outcomes, screening only creates labels, anxiety, and procedures (overdiagnosis pathway). Combine with lead-time/length-time concepts from Section 18.1.
False-Positive Burden
Even excellent tests harm at scale.
Worked example 7 — Population false positives
Screen 100,000 people, prevalence 0.2% (200 true cases), Sn 99%, Sp 99%:
- TP = 0.99 × 200 ≈ 198
- FN ≈ 2
- FP = 0.01 × 99,800 ≈ 998
- PPV ≈ 198/(198+998) ≈ 16.5%
About five false positives per true positive . Each FP may trigger invasive biopsy, radiation, or labeling—false-positive burden is a core screening harm, not a footnote.
Integration for CBSE Vignettes
Write the 2×2; identify which margin is fixed (disease totals vs test totals).
Sn/Sp use disease columns; PPV/NPV use test rows.
If prevalence falls and Sn/Sp fixed, expect PPV ↓, NPV ↑ .
"Best test to rule out" → maximize sensitivity (or favorable LR−).
"Best to confirm" → maximize specificity (or favorable LR+).
Continuous biomarker + threshold debate → ROC/cutoff tradeoff.
Two-step algorithm → serial testing for specificity.
Community screening pitch with unchanged mortality → question overdiagnosis/lead time/false positives, not only Sn.
Master the arithmetic and the prevalence story; most diagnostic-test items are variants of Examples 1–3 and 7.